Is bisphosphonate therapy a risk factor for subtrochanteric femoral fractures?

David Burr

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The rate of bone turnover in the femoral shaft is normally quite low. In some patients being treated with alendronate, the remodeling rate may have been excessively low. This suggests that before a patient is given a bisphosphonate, biomarkers related to bone resorption and formation should be measured.

Original languageEnglish
Pages (from-to)57-58
Number of pages2
JournalJournal of the American Academy of Orthopaedic Surgeons
Volume17
Issue number1
StatePublished - Jan 2009
Externally publishedYes

Fingerprint

Femoral Fractures
Hip Fractures
Diphosphonates
Alendronate
Bone Remodeling
Bone Resorption
Thigh
Osteogenesis
Biomarkers
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Is bisphosphonate therapy a risk factor for subtrochanteric femoral fractures? / Burr, David.

In: Journal of the American Academy of Orthopaedic Surgeons, Vol. 17, No. 1, 01.2009, p. 57-58.

Research output: Contribution to journalArticle

@article{e4a35ca6798c4e94a67c0db7d5bd5cb9,
title = "Is bisphosphonate therapy a risk factor for subtrochanteric femoral fractures?",
abstract = "The rate of bone turnover in the femoral shaft is normally quite low. In some patients being treated with alendronate, the remodeling rate may have been excessively low. This suggests that before a patient is given a bisphosphonate, biomarkers related to bone resorption and formation should be measured.",
author = "David Burr",
year = "2009",
month = "1",
language = "English",
volume = "17",
pages = "57--58",
journal = "The Journal of the American Academy of Orthopaedic Surgeons",
issn = "1067-151X",
publisher = "American Association of Orthopaedic Surgeons",
number = "1",

}

TY - JOUR

T1 - Is bisphosphonate therapy a risk factor for subtrochanteric femoral fractures?

AU - Burr, David

PY - 2009/1

Y1 - 2009/1

N2 - The rate of bone turnover in the femoral shaft is normally quite low. In some patients being treated with alendronate, the remodeling rate may have been excessively low. This suggests that before a patient is given a bisphosphonate, biomarkers related to bone resorption and formation should be measured.

AB - The rate of bone turnover in the femoral shaft is normally quite low. In some patients being treated with alendronate, the remodeling rate may have been excessively low. This suggests that before a patient is given a bisphosphonate, biomarkers related to bone resorption and formation should be measured.

UR - http://www.scopus.com/inward/record.url?scp=58449097845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58449097845&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 57

EP - 58

JO - The Journal of the American Academy of Orthopaedic Surgeons

JF - The Journal of the American Academy of Orthopaedic Surgeons

SN - 1067-151X

IS - 1

ER -